Most Read Articles
Pearl Toh, 6 days ago
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Roshini Claire Anthony, 3 days ago

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.

Statin use tied to decreased acute pancreatitis severity

08 Sep 2018
Statin, a blood cholesterol-lowering medicine, reduces sharply in blood cholesterol levels among ACS patients.

Use of statins may reduce the severity of acute pancreatitis (AP) seen in the decrease of overall incidence of multisystem organ failure (MSOF) and new MSOF, suggests a recent study.

Adult patients with AP admitted in the Cleveland Clinic Health System between 2007 and 2014 were included in this historical cohort study. Electronic medical records were extracted to obtain all medication, clinical and outcomes data. To minimize selection bias, factors influencing statin use were included in a propensity model.

The authors matched patients on and off statins based on the propensity score to simulate a randomized controlled trial. Measured outcomes included pancreatitis severity (Revised Atlanta Classification), MSOF incidence, new MSOF, acute necrosis and death. Additional surrogate markers of severity were as follows: hospital length of stay, Bedside Index of Severity of Acute Pancreatitis (BISAP) and presence of systemic inflammatory response syndrome.

A total of 110 patients on statins at admission were matched with 210 individuals not on statins. The two groups had evenly matched known baseline factors that might influence statin use and severity of pancreatitis.

Patients in the statin group were less likely to develop MSOF, severe AP and necrosis. Lower in-hospital deaths were reported in the statin group vs nonusers, but the difference was not statistically significant (2 percent vs 4 percent; p=0.38).

“Prospective randomized controlled trials are needed to determine the efficacy of statin drugs in the treatment of AP,” the authors said.

“Statins possess anti-inflammatory properties and have a protective effect in certain inflammatory conditions. However, their effect on the natural history of pancreatitis is unknown,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Roshini Claire Anthony, 3 days ago

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.